StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Eberconazole

HCID 72051
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
128326-82-9
Standard-SMILES
Clc1cc(Cl)c2c(c1)CCc1ccccc1C2n1ccnc1
InChIKey
MPTJIDOGFUQSQH-UHFFFAOYSA-N
Summenformel
C18H14Cl2N2
Durchschnittliche Molmasse
329,2 g/mol
Monoisotopische Masse
328,0534038

Überblick

1-(2,4-dichloro-10,11-dihydrodibenzo[a,d][7]annulen-5-yl)imidazole is a member of the class of dibenzannulenes that is 10,11-dihydrodibenzo[a,d][7]annulene carrying two chloro substituents at positions 2 and 4 as well as an imidazol-1-yl substituent at position 5. It is a member of imidazoles, a dibenzannulene and an organochlorine compound. It derives from a hydride of a dibenzo[a,d][7]annulene.

Namen und Bezeichner

Bevorzugter Name
Eberconazole
IUPAC
1-(4,6-dichloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)imidazole
Englischer Name
Eberconazole
Summenformel
C18H14Cl2N2
Molmasse
329.22

Namen und Synonyme

Eberconazole128326-82-9EberconazolEberconazolumV7O1U41C9BDTXSID909261041-(2,4-dichloro-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)-1H-imidazoleRefChem:920795CHEBI:82862D01AC17DTXCID6013549231-(4,6-dichlorotricyclo(9.4.0.0^(3,8))pentadeca-1(15),3,5,7,11,13-hexaen-2-yl)-1H-imidazole
Weitere Namen anzeigen
1H-Imidazole, 1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(+/-)-1-(2,4-Dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)imidazole
Eberconazole [INN]1-(4,6-dichloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,11,13-hexaenyl)imidazole1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)-1H-imidazoleEberconazole (INN)Eberconazol [INN-Spanish]Eberconazolum [INN-Latin]UNII-V7O1U41C9BWAS-2160

Datenbank-Bezeichner

CAS
128326-82-9

Eigenschaften

Berechnete Struktureigenschaften

XLogP
4,9
Polarare Oberfläche (TPSA)
17,8 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
1
Frei drehbare Bindungen
1
Schwere Atome
22
Formalladung
0
Komplexität
391

Physikochemische Eigenschaften

Siedepunkt
495 · 495.0±45.0 °C(Predicted)
Dichte
1.35 · 1.35±0.1 g/cm3(Predicted)
pka
5.84 · 5.84±0.10(Predicted)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

D - Dermatologicals

QD - Dermatologicals

PharmacodynamicsEberconazole is active against Gram-positive bacteria, dermatophytes, and yeasts.
Mechanism of ActionEberconazole shares a mechanism of action with other antimycotic azoles: It inhibits lanosterol 14a-demethylase, thereby blocking the synthesis of precursors of ergosterols.
Anwendungen · 2 Einträge

BeschreibungEberconazole is a new member of the azole class of antifungal agents, and it is indicated for the topical treatment of cutaneous fungal infections, including tinea corporis (ringworm of the body), tinea cruris (ringworm of the groin) and tinea pedis (athlete’s foot) infections. Its mode of action is similar to that of other azole antifungals, namely inhibition of fungal lanosterol 14α-demethylase. Eberconazole exhibits good in vitro activity against a wide range of Candida species, including Candida. tropicalis, dermatophytes and Malassezia spp. yeasts. It shows good activity against Candida. Parapsilosis (MIC90=0.125 mg/mL), which is a relevant species in skin and nail disorders. In addition, eberconazole is effective against some of the highly triazole-resistant yeasts such as Candida. glabrata and Candida. krusei, as well as fluconazole-resistant Candida. albicans. However, eberconazole is less active than clotrimazole and ketoconazole against Candida. neoformans and a number of clinically relevant molds. Eberconazole is supplied as a 1% or 2% cream, and the topical application does not result in detectable serum, urine, or fecal levels. In a phase II study of 60 patients with tinea corporis and tinea cruris, treatment with topical eberconazole (1% or 2% cream), applied once or twice daily for 6 weeks, resulted in cure rates ranging from 73.3–93.3% at the end of therapy, and 66.7–100% six weeks post-therapy.

VerwendenEberconazole can be used for a novel antifungal formulation.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
PubChem CID
72051
DTXSID
DTXSID90926104
ChEMBL
CHEMBL558722
ChEBI
CHEBI:83584
UNII
V7O1U41C9B
Nikkaji
J561.862B